Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.

Heron Therapeautics Inc

HRTX
1,58
0,03 (1,94%)
14 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
23/12/202422:05EDGAR2Form 8-K - Current report
23/12/202422:05PRNUSHeron Therapeutics Announces Corporate Headquarters..
04/12/202414:45APSWall Street Analysts Were Busy This Morning
03/12/202423:15EDGAR2Form 8-K - Current report
03/12/202422:36PRNUSU.S. District Court Upholds Validity of CINVANTI® Patents
12/11/202414:06EDGAR2Form 8-K - Current report
12/11/202413:55PRNUSHeron Therapeutics Announces Third Quarter 2024 Financial..
06/11/202420:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/11/202418:41EDGAR2Form 3 - Initial statement of beneficial ownership of..
04/11/202423:09EDGAR2Form 8-K - Current report
04/11/202423:00PRNUSHeron Therapeutics Announces Appointment of Michael Kaseta..
29/10/202421:05PRNUSHeron Therapeutics to Report Third Quarter 2024 Financial..
24/10/202420:02EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
21/10/202421:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/10/202421:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/10/202421:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/10/202422:08PRNUSHeron Therapeutics Reaffirms Availability and Ample Supply..
25/9/202414:00PRNUSHeron Therapeutics Announces FDA Approval of the Prior..
03/9/202414:00PRNUSHeron Therapeutics Announces Appointment of Brett Fleshman..
06/8/202422:35EDGAR2Form S-8 - Securities to be offered to employees in employee..
06/8/202422:05EDGAR2Form 8-K - Current report
06/8/202422:05PRNUSHeron Therapeutics Announces Second Quarter 2024 Financial..
30/7/202422:05PRNUSHeron Therapeutics to Report Second Quarter 2024 Financial..
22/7/202415:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/7/202415:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/7/202415:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/7/202414:00PRNUSHeron Therapeutics Announces the Inclusion of ZYNRELEF® as a..
02/7/202414:00PRNUSHeron Therapeutics Announces Acceptance of the Prior..
18/6/202422:43EDGAR2Form 8-K - Current report
17/6/202420:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202415:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/5/202417:08EDGAR2Form SC 13D/A - General statement of acquisition of..
29/5/202414:05EDGAR2Form 8-K - Current report
29/5/202414:05PRNUSHeron Therapeutics Announces Prior Approval Supplement..
07/5/202414:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202414:05EDGAR2Form 8-K - Current report
07/5/202414:00PRNUSHeron Therapeutics Announces First Quarter 2024 Financial..
24/4/202414:00PRNUSHeron Therapeutics to Report First Quarter 2024 Financial..
11/4/202422:05PRNUSHeron Therapeutics to Host Investor Day on May 15, 2024 in..
28/3/202421:05PRNUSHeron Therapeutics Announces Presentation at the 23rd Annual..
13/3/202421:25APSBiotech Finds Mid-Week Success Following Q4 Earnings Release
12/3/202421:05PRNUSHeron Therapeutics Announces Fourth Quarter and Full-Year..
12/3/202412:22IHMARKETNEWSGlobal Markets Await U.S. Inflation Report: Mixed Movements..
28/2/202414:00PRNUSHeron Therapeutics to Report Fourth Quarter and Full Year..
14/2/202422:37EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202422:21EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
24/1/202415:25APSPremarket Heats Up For Biotech Before Opening Bell
24/1/202414:01EDGAR2Form 8-K - Current report
24/1/202402:00PRNUSHeron Therapeutics Announces FDA Approval of ZYNRELEF®..
20/1/202403:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 1,52 Min: 1,48 Max: 1,55
Chiusura: 1,55

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network